DPEP1
ENSG00000015413
Target class
Enzyme
Chromosome
16
Approved drugs
2
Clinical candidates (approved and in development)
2
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Target name
- DPEP1
- Gene name
- Dipeptidase 1
- Gene symbol
- DPEP1
- Protein name
- Dipeptidase 1 (EC 3.4.13.19) (Beta-lactamase) (EC 3.5.2.6) (Dehydropeptidase-I) (Microsomal dipeptidase) (Renal dipeptidase) (hRDP)
- Gene biotype
- Protein coding
- Gene family
- M19 metallopeptidases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 14
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 229.85
- Tissue specificity (Gini)
- 0.912
- Tissue specificity (tau)
- 0.96
- KEGG gene identifiers
- hsa:1800
- R-HSA-2142691
- R-HSA-5423646
- R-HSA-9664535
- End position
- 89638456
- Start position
- 89613308
- Chromosome
- 16
- Strand
- Forward
- Apical cell membrane
- Lipid-anchor, GPI-anchor . Cell projection, microvillus membrane
- Lipid-anchor, GPI-anchor . Note=Brush border membrane. .
- Cell Junctions
- PubMed 28413640
- PubMed 2168407
- Tissue specificity (tau)
- 0.959846
- Expression inequality (Gini)
- 0.912357
Expression in transcripts per million
- Small Intestine - Terminal Ileum
- 229.85
- Pancreas
- 169.81
- Kidney - Cortex
- 145.63
- Testis
- 110.29
- Kidney - Medulla
- 33.48
Expression in transcripts per million
- Small Intestine - Terminal Ileum229.85
- Pancreas169.81
- Kidney - Cortex145.63
- Testis110.29
- Kidney - Medulla33.48
- Spleen4.44
- Cervix - Ectocervix3.83
- Ovary1.93
- Adrenal Gland1.91
- Fallopian Tube1.43
- Stomach1.22
- Cervix - Endocervix1.17
- Thyroid1.07
- Lung1.04
- Vagina0.91
- Skin - Sun Exposed (Lower leg)0.89
- Colon - Transverse0.88
- Minor Salivary Gland0.85
- Breast - Mammary Tissue0.76
- Cells - Cultured fibroblasts0.72
- Nerve - Tibial0.68
- Pituitary0.58
- Skin - Not Sun Exposed (Suprapubic)0.57
- Prostate0.54
- Uterus0.52
And 29 more, listed on the interactive page.
- GO:0006749
- GO:0016999
- GO:0030336
- GO:0050667
- GO:0072340
- GO:1901749
- GO:0005886
- GO:0016324
- GO:0030054
- GO:0045177
- GO:0070062
- GO:0005515
- GO:0008235
- GO:0008270
- GO:0008800
- GO:0016805
- GO:0070573
- GO:0072341
Related records
Trials (38)
- A Double-blind Non Inferiority Clinical Trial to Compare the Nephroprotection of Cilastatn Versus Thiosulfate in Patients Undergoing Debulking Surgery With Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Cisplatin.
- A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia
- A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)
- A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
- A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
- A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired During Hospitalization
- A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection
- A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
- A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis
- Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection
- Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections
- Comparing Efficacy and Safety of (Meropenem + Colistin) Versus (Imipenem/Cilastatin + Tigecycline) on Eradication of Multi-Drug Resistance Bacteria
- Complicated Skin and Skin Structure Infections
- Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis
- Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)
- Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)
- Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections
- Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects
- GSK2251052 in Complicated Urinary Tract Infection
- Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)
Drugs (2)
- Cilastatin Renal dipeptidase inhibitor
- Cilastatin sodium Renal dipeptidase inhibitor